Goal: To learn how to calculate EFS,OS, TRM, how to create Kaplan Meier curves and CI curves. The difference between CI and Kapolan Meier was discussed. Corresponding literature from ALPWP EBMT is provided. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas.

Goal: To learn the differences between RIC, RTC, MAC, NMA, etc. Corresponding literature is provided. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas

Goal: To learn how to deceide whether we should get an older person to transplant. Literature and cases are presented. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.

Goal: To understand the structure of donor registries. Learn corresponding terminology. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.

Goal:To learn about Bite, inotuzumab and CART therapies. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas

Goal: Which graft is better to use in haplo PTCY transplant? Dr Liga presented the current literature. We deceide the following policy CR-1 BM, advanced disease PBSC. Presenter: Dr Liga Participants: Prof. Spyridonidis, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.

Goal: An overview of the haplo PTCY platform. Presenter: Dr Liga. Participants: Prof. Spyridonidis, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.

Goal: Principles of Donor selection. Quiz and examples were shown. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Triantafyllou  

Goal: to get an overview of current cellular therapies and learn where we stand. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou

a reent  study publisghed at LEukemia confirms the role of upfront ASCT in MM. Upfornt autolgous is the standrd of care in MM Presenter: Spyridonidis Patriciapnts: all medical staff

The FDA approved tisagenlecleucel (Kymriah) for certain paediatric and young adult patients with B-cell acute lymphoblastic leukaemia (ALL). The cell-based gene therapy is approved in the United States for the treatment of patients up to 25 years of age with B-cell precursor ALL that...

Combined use of global and targeted analyses allows the cytogenetic classification of 88% of adult patients with Ph-negative BCP-ALL. • In GRAALL trials, t(4;11)/KMT2A-AFF1 and t(v;14q32)/IGH are the two cytogenetic anomalies significantly associated with a worse outcome. Combined use of global and targeted analyses allows the cytogenetic...

We often see such patients and the question is raised whether transplant could help these poatients. A rertrospetive analysis from the Italian transplant centers tries to answer this. There ia an accompayiong editorial on this analysis. Presenter: Spyridonidis participants: all medical staff 

Venetoclax Gets Breakthrough-Therapy Designation for AML At 12-month follow-up, the overall response rate was 44 percent (complete remission, n=4; complete remission without complete marrow recovery, n=4; resistant disease, n=8; death before evaluation, n=2). FDA Approves Combination Daunorubicin and Cytarabine for High-Risk AML The drug was approved based on...

Wediscussed the incidence and diagnosis of IDH mutations in AML. The new approved drug may prove very helpful for these patients Presenter: Spyridonidis Participants: all medical staff   The US Food and Drug Administration (FDA) has approved enasidenib (Idhifa) for the treatment of relapsed or refractory...

Extended analysis of the fiorst randomized ATG trial in BMT. Presenter: Spyridonidis Participants: All medical staff

Excellent paper by John Dicks group published in Nature. The study identifies the reasosn  why some aptrients relapse also amny years after chemothertpay or allogheneic BMT. Presenter: Spyridonidis Participants: All medical staff